Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Smart blood test guides treatment for stubborn hodgkin lymphoma

NCT ID NCT07021989

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 39 times

Summary

This study tests a combination of the immunotherapy drug pembrolizumab and three chemotherapy drugs (GVD) in 38 adults whose Hodgkin lymphoma returned or did not respond to one prior treatment. A special blood test (ctDNA) is used to see how well the treatment is working and to guide next steps. The goal is to achieve a complete response, meaning no cancer is detectable by both the blood test and PET scan.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California Davis

    Davis, California, 95616, United States

  • University of California Irvine

    Irvine, California, 92617, United States

  • University of California San Francisco-Fresno

    Fresno, California, 93701, United States

  • University of California, San Diego

    La Jolla, California, 92093, United States

  • University of California, San Francisco

    San Francisco, California, 94143, United States

    Contact

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Unversity of California, Los Angeles

    Los Angeles, California, 90095, United States

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.